SUVEN

Masupirdine

This clinical trial is testing Masupirdine‘s effectiveness on calming agitation that often affects those with Alzheimer’s disease. This oral medication is a selective antagonist of the 5-HT6 serotonin receptor.

Eligibility: Individuals with Alzheimer’s disease with untreated agitation.

Status: RECRUITING

Application











    All information provided is confidential and will not be given or sold to any other agency without prior consent.